BioSpace News Archive

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814).

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:

AIM ImmunoTech Inc. issued a notice that the Company has learned that unknown person and/or organization are claiming to represent AIM ImmunoTech Europe and are using the Company’s name without authorization.

ENB Therapeutics, Inc. today announced that the company has completed enrollment of its international Phase 1 ENBOLDEN-101 trial investigating the safety and efficacy of lead product ENB-003 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Endologix LLC announced today that the first patients underwent Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR system, since FDA approval of the system was granted.

Medcura Inc., proudly announces the appointment of Jacob Rodman to its Board of Directors.

Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), presented three posters at the Alzheimer’s Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16-20.

BioCorRx Inc. today announced the submission of a fast track application to the U.S. Food and Drug Administration (“FDA”) for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).

Baird Medical Investment Holdings Limited announced today that the Company’s independently developed and produced disposable MWA needle for the treatment of benign thyroid nodules received approval from China’s National Medical Products Administration (the “NMPA”) on July 13, 2023.

PDO Max, Inc., a leader in FDA cleared Polydioxanone threads-in-cannula medical devices for non-surgical tissue repositioning, recently assembled its training team for its annual training conference, in Boston, to ensure their 25 trainers have the latest techniques and product knowledge.